Revenue segments as reported by the company.

Transcatheter Aortic Valve Replacement

Transcatheter Mitral and Tricuspid Therapies

Surgical Structural Heart

Critical Care

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative expenses

Research and development expenses

Intellectual property litigation expenses, net

Change in fair value of contingent consideration liabilities

Special charges

Restructuring expenses

Other operating expenses, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring systems measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Edwards Lifesciences projects robust sales growth amidst market advancements

Edwards Lifesciences showcased strong sales growth and financial performance in Q4 2022. Despite challenges like FX impacts and spotty backlog, the company remains confident in its growth outlook. Encouraging opportunities lie in TMTT and Surgical Structural Heart segments for future expansion.

Edwards Lifesciences reports robust Q1 sales, eyes global expansion

Edwards Lifesciences delivered strong sales performance in Q1, driven by key product segments and global growth.
The company faces challenges in managing expenses and navigating competitive dynamics, particularly in Japan.
Opportunities lie in continued market growth, product innovation, and efficiency enhancements across operations.
Overall, Edwards Lifesciences remains well-positioned for growth and market leadership in the cardiovascular space.

Edwards Lifesciences exceeds Q2 expectations, raises full-year guidance

Edwards Lifesciences delivered strong Q2 results, raising full year guidance and highlighting growth in key segments. While facing challenges like seasonal impacts and market recovery issues, the company remains focused on innovation and market expansion.

Edwards Lifesciences excels in Q3, poised for diversified growth

Edwards Lifesciences delivered a strong Q3 performance with growth across key segments and a positive outlook for 2023.
The company's focus on innovation, differentiated sales strategies, and patient-centric initiatives position it well for future growth.
Challenges in pricing dynamics and market competition require strategic management, while opportunities in diverse therapies and patient activation initiatives offer avenues for expansion.
Overall, Edwards Lifesciences maintains a solid financial position, supported by a robust balance sheet and a commitment to long-term growth.

Edwards Lifesciences posts strong Q4 results, eyes global growth opportunities

Edwards Lifesciences' Q4 2023 performance reflects solid financial health and strategic investments for future growth. Despite facing challenges such as rising expenses and competitive pressures, the company is well-positioned to capitalize on opportunities through innovation and market expansion.

Edwards Lifesciences reports robust Q1 sales growth and outlook

Edwards Lifesciences shows strong sales growth across key segments and raises 2024 outlook.
Investments in transcatheter platforms and positive milestones drive sustainable growth.
Challenges include managing increased expenses and ensuring center readiness for new therapies.
Opportunities in AI implementation, patient care initiatives, and diversified growth potential.

Edwards Lifesciences reports strong Q3 performance and strategic growth focus

Edwards Lifesciences delivered robust Q3 results driven by TAVR and TMTT growth, showcasing resilience and innovation.
While facing challenges in certain markets like Japan, Edwards maintains a strong competitive position and strategic focus on long-term growth.
The company's acquisitions, product advancements, and maintained guidance reflect a commitment to expansion and market leadership.
With opportunities in innovation and global expansion, Edwards is poised for continued growth and success in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Crown Castle International

Moody's

Sherwin-Williams

The GuruFocus business predictability rating ranks companies on a five-star scale, defining the more predictable companies as businesses whose revenue per share and Ebitda per share have been growing steadily and who have produced a strong long-term performance of their stock prices.

4 Stock Picks for a 'Buy and Hold' Approach

A few months back we discussed that Edward Lifesciences stock may continue to see higher levels after rising 10% in a month following the positive developments around Resilia tissue valves. EW stock has since rallied 16% to levels of $121 currently.

What's Happening With Edward Lifesciences Stock?

Graco

Lululemon Athletica

Masimo

USANA Health Sciences

According to the “Good Companies Screen,” one of several Premium screens under the All-in-One Screener, five stocks with high financial strength and profitability are Edwards Lifesciences Corp. ( EW , Financial), Lululemon Athletica Inc. ( LULU , Financial), Masimo Corp. ( MASI , Financial), Graco Inc. ( GGG , Financial) and Usana Health Sciences Inc. ( USNA , Financial).

5 Good Companies With High Profitability

Investors are optimistic about Edwards Lifesciences (EW) on strong sales growth across all four product groups in the second quarter and raised 2021 guidance.

Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?

Amazon

Mastercard

Pinterest

Agios Pharmaceuticals

Chubb

Citrix Systems

Gilead Sciences

With the trading day nearly halfway over, the broad markets were pulling back into the weekend.

Amazon, Mastercard, Pinterest and More Friday Afternoon Analyst Upgrades and Downgrades

Strong sales growth across all four products along with steady improvement in surgical procedure volumes during the second quarter drove Edwards Lifesciences' (EW) revenues.

Edwards Lifesciences (EW) Beats on Q2 Earnings, Margins Up

Edwards Lifesciences (NYSE: EW), a cardio device company, reported Q2 earnings of $489.5 million, or $0.64, ahead of the consensus of $0.55. "Vaccine adoption in key regions has contributed to an increased number of patients seeking and, most importantly, receiving treatment," CEO Michael A.

Edwards Lifesciences Beats Q2 Earnings On Demand Recovery, Boosts FY2021 Guidance; Analysts Raise Price Target

Edwards Lifesciences Corporation (EW) CEO Mike Mussallem on Q2 2021 Results - Earnings Call Transcript

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 16.36% and 7.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences (EW) Q2 Earnings and Revenues Surpass Estimates

Edwards Lifesciences presents with the economic pillars that round out a robust investment case. Central to the sell-side's thesis is EW's valuation, which we firmly believe is justified at 46X earnings and 36X EBITDA.

Edwards Lifesciences: TAVR And TMTT Strengths Key Growth Levers

Continued adoption of TruWave disposable pressure monitoring devices and progress in transfemoral EVOQUE and SAPIEN M3 platforms are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.

What's in Store for Edwards Lifesciences (EW) Q2 Earnings?

IRVINE, Calif., July 22, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced that clinical and economic results from the 3M (multidisciplinary, multimodality, but minimalist) Transcatheter Aortic Valve Replacement (TAVR) Economic Study and the PARTNER 3 Bicuspid Registry for SAPIEN 3 TAVR Study were presented at TVT 2021: The Structural Heart Summit.

Study Data Presented at TVT on the Economics of Minimalist TAVR, PARTNER 3 Bicuspid TAVR

IRVINE, Calif., July 22, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2021 after the market closes on Thursday, July 29, 2021, and will host a conference call at 5:00 p.m.

Edwards Lifesciences To Host Earnings Conference Call On July 29, 2021

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Q2 Release

Texas Instruments

Nio, Facebook, Edward Lifesciences and Texas Instruments were our top stock trades for Tuesday. Let's look at how the charts are setting up.

4 Top Stock Trades for Tuesday: NIO, FB, EW, TXN

The stock price of Edward Lifesciences, a company specializing in artificial heart valves and hemodynamic monitoring, has seen a rise of 10% in the last twenty-one trading days. This can be attributed to the positive outcome from a clinical trial for Evoque tricuspid and Pascal system for patients.

Edwards Lifesciences May Continue To Rise After Positive Clinical Trial Data

Becton, Dickinson and Co.

Boston Scientific

Medtronic

Merit Medical Systems

These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.

Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on

IRVINE, Calif., June 1, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced that Acumen Hypotension Prediction Index (HPI) software with the Acumen IQ finger cuff has received U.S. Food and Drug Administration clearance.

Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock?

Edwards Lifesciences (EW) Down 4.8% Since Last Earnings Report: Can It Rebound?

IRVINE, Calif., May 18, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Aortic Valve Replacement (TAVR) and at low risk of death from surgery.

Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR

IRVINE, Calif., May 18, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced that clinical results from the company's transcatheter mitral and tricuspid programs were presented as part of the late-breaking clinical trials at EuroPCR 2021, demonstrating positive outcomes for patients impacted by mitral or tricuspid heart valve disease.

Clinical Data Updates On Edwards' Transcatheter Mitral, Tricuspid Programs Presented At EuroPCR

IRVINE, Calif., May 5, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced updates from its annual meeting, in which Edwards' stockholders voted with the board's recommendations on all proxy proposals: All eight director nominees were elected as directors of the company for a one-year term; Stockholders advised that they approve the compensation of the company's named executive officers; Stockholders have approved the Amendment and Restatement of the company's U.S. and International Employee Stock Purchase Plans; Stockholders have ratified the appointment of the company's independent registered public accounting firm for fiscal year 2021; Stockholders have advised that they do not approve the stockholder proposal regarding action by written consent; and Stockholders have advised that they do not approve the stockholder proposal to adopt a policy to include non-management employees as prospective director candidates.

Edwards Announces Updates From Annual Meeting

Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Edwards Lifesciences (EW) Surges 6.3%: Is This an Indication of Further Gains?

Intuitive Surgical

Edwards Lifesciences Corp. (NYSE:EW) and Intuitive Surgical Inc. (NASDAQ:ISRG) are on the Wall Street radar this week.

Edwards Lifesciences and Intuitive Surgical: Right Place, Right Time and Wide Moats

ORANGE COUNTY, Calif., April 21, 2021 /PRNewswire/ -- Providence, a national nonprofit health system, is partnering with Edwards Lifesciences (NYSE: EW), the Orange County-based medical technology company, and the Cities of Irvine, Santa Ana, Costa Mesa and Tustin to open two mass vaccination clinics at one of Edwards Lifesciences' campus buildings in Santa Ana and the Orange County Great Park in Irvine, providing convenient access for residents to protect themselves from COVID-19.

News for Edwards Lifesciences Stock (EW)